Bio-Rad reaffirms 2026 currency-neutral revenue growth at (-3%) to 0.5% while targeting non-GAAP operating margin in upper half of 10% to 12% range
Open the sourceReported by Seeking Alpha, seekingalpha.com, 5 November 2026
Not scored
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Muhabbit only has the headline for this one. The full report is at seekingalpha.com.